+

PE20181208A1 - Metodos de modulacion de moleculas de vigilancia de adn citosolicas - Google Patents

Metodos de modulacion de moleculas de vigilancia de adn citosolicas

Info

Publication number
PE20181208A1
PE20181208A1 PE2017002822A PE2017002822A PE20181208A1 PE 20181208 A1 PE20181208 A1 PE 20181208A1 PE 2017002822 A PE2017002822 A PE 2017002822A PE 2017002822 A PE2017002822 A PE 2017002822A PE 20181208 A1 PE20181208 A1 PE 20181208A1
Authority
PE
Peru
Prior art keywords
methods
modulation
cytosolic dna
molecules
dna surveillance
Prior art date
Application number
PE2017002822A
Other languages
English (en)
Inventor
Thomas Ilg
Albert Abraham
Jason Nickell
Daniel Keil
Christian Weiss
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20181208A1 publication Critical patent/PE20181208A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Metodos para generar una respuesta inmunologica en un sujeto mediante la activacion de moleculas y vias de senalizacion de inmunidad innata especificas. En particular, se usa una composicion inmunomoduladora para estimular moleculas y vias de senalizacion de inmunidad innata.
PE2017002822A 2015-06-26 2016-06-23 Metodos de modulacion de moleculas de vigilancia de adn citosolicas PE20181208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26

Publications (1)

Publication Number Publication Date
PE20181208A1 true PE20181208A1 (es) 2018-07-23

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002822A PE20181208A1 (es) 2015-06-26 2016-06-23 Metodos de modulacion de moleculas de vigilancia de adn citosolicas

Country Status (22)

Country Link
US (1) US20190233825A1 (es)
EP (1) EP3313376A2 (es)
JP (1) JP2018518511A (es)
KR (1) KR20180021874A (es)
CN (1) CN108472255A (es)
AR (1) AR105160A1 (es)
AU (1) AU2016282879A1 (es)
BR (1) BR112017028121A2 (es)
CA (1) CA2990526A1 (es)
CL (1) CL2017003373A1 (es)
CR (1) CR20180003A (es)
DO (1) DOP2017000313A (es)
HK (1) HK1256128A1 (es)
IL (1) IL256264A (es)
MX (1) MX2017017141A (es)
PE (1) PE20181208A1 (es)
PH (1) PH12017502413A1 (es)
RU (1) RU2018102915A (es)
SG (1) SG10201913395VA (es)
TW (1) TW201710509A (es)
UY (1) UY36756A (es)
WO (1) WO2016207314A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
JP2019525935A (ja) 2016-07-26 2019-09-12 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ ウシ種の繁殖力の増加
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
ES2320315T5 (es) * 1994-07-15 2012-12-05 University Of Iowa Research Foundation Oligonucleótidos inmunoestimuladores
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CA2423093C (en) * 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
PE20050386A1 (es) * 2003-05-29 2005-06-23 Schering Plough Ltd Composiciones farmaceuticas de florfenicol
JP2008511545A (ja) * 2004-08-13 2008-04-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失ｄｎａワクチン
JP5530065B2 (ja) * 2004-08-13 2014-06-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗生物質耐性欠失ワクチンの作成方法
PE20120903A1 (es) * 2009-05-14 2012-08-01 Bayer Ip Gmbh Respuesta inmunitaria reforzada en especies aviares
PL2654785T3 (pl) * 2010-12-22 2019-09-30 Bayer Intellectual Property Gmbh Wzmocniona odpowiedź immunologiczna u gatunków wołowatych
EP2714907B1 (en) * 2011-05-26 2016-06-15 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids

Also Published As

Publication number Publication date
KR20180021874A (ko) 2018-03-05
WO2016207314A2 (en) 2016-12-29
RU2018102915A (ru) 2019-07-29
AU2016282879A1 (en) 2018-01-18
AR105160A1 (es) 2017-09-13
WO2016207314A3 (en) 2017-02-09
RU2018102915A3 (es) 2019-12-05
IL256264A (en) 2018-02-28
DOP2017000313A (es) 2018-02-28
EP3313376A2 (en) 2018-05-02
CA2990526A1 (en) 2016-12-29
CR20180003A (es) 2018-03-20
BR112017028121A2 (pt) 2018-09-04
UY36756A (es) 2017-01-31
JP2018518511A (ja) 2018-07-12
CL2017003373A1 (es) 2018-06-29
US20190233825A1 (en) 2019-08-01
HK1256128A1 (zh) 2019-09-13
CN108472255A (zh) 2018-08-31
MX2017017141A (es) 2018-03-09
SG10201913395VA (en) 2020-03-30
TW201710509A (zh) 2017-03-16
PH12017502413A1 (en) 2018-06-25

Similar Documents

Publication Publication Date Title
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX387055B (es) Agonistas del receptor de apelina (apj) y usos de los mismos.
MA40595A (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
MX376105B (es) Método para producir l-aminoacidos utilizando una bacteria alcalifílica.
DK3218076T3 (da) System og fremgangsmåde til legetøjsgenkendelse
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
DOP2017000313A (es) Métodos de modulación de moléculas de vigilancia de adn citosólicas
EP3547906A4 (en) SEMIOLOGY OF EPILEPSY ATTACKS INCLUDING MUSCLE SIGNALS COLLECTED FROM ELECTROENCEPHALOGRAPHY ELECTRODES
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201691374A1 (ru) Инсулин длительного действия и его применение
MX385788B (es) Método de tratamiento con tradipitant.
ITUA20161903A1 (it) Capsula per ottenere bevande e metodo di produzione della stessa
DK3159296T3 (da) Reb til elevator og fremstillingsfremgangsmåde dertil
EA201591720A1 (ru) Белки, специфические по отношению к baff и b7rp1, и их применение
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
DK3093022T3 (da) Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma
EP3862937C0 (en) Generating weather forecasts with human over-the-loop oversight
DK3147351T3 (da) Mikroorganisme med forbedret intracellulært energiniveau og fremgangsmåde til fremstilling af L-aminosyre under anvendelse deraf
EP3137649C0 (en) METALLIZATION OF SURFACES
DK3144383T3 (da) Mikroorganisme af Corynebacterium-slægten til fremstilling af L-lysin og fremgangsmåde til fremstilling af L-lysin under anvendelse af denne
EP3359675A4 (en) ACTIVATION OF IMMUNOUSED SIGNALING PATHS IN CELLS BY OPTOFEKTION
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载